Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Skywatcher who wrote (281)	6/16/2000 8:03:00 PM
From: John McCarthy	Read Replies (2) \| Respond to of 328

Question about paclitaxel and NPRO ... Hi - I am long NPRO. As you may or may not know, NPRO/ABT are teamed up to sell paclitaxel. Recently, IVAX defeated BMY in court over the rights to sell a generic version of paclitaxel and won. (BMY's product goes by the retail name Taxol) In as much as IVAX uses the NPRO paclitaxel FORMUALATION (which is patented) does anyone know whether (1) ABT will soon change direction and file with the FDA to sell a generic version of NPRO'S paclitaxel or (2) continue to develop (via clincial trials) a unique version of paclitaxel co-developed by NPRO and ABT? The paclitaxel market right now is approx. $2.0 billion worldwide. Any comments, insights, or facts would be appreciated. regards, John McCarthy